ANN ARBOR, Mich., April 20, 2011 /PRNewswire/ — Adeona
Pharmaceuticals, Inc. (NYSE Amex:
AEN), a developer of innovative medicines for serious central
nervous system diseases, announced today that it has executed an
agreement with TG United, Inc. of Brooksville, Florida, to provide
commercial-scale manufacturing capabilities for reaZin.
Adeona is developing reaZin, its product candidate for the
dietary management of Alzheimer’s disease and mild cognitive
impairment, as a prescription medical food.
Top-line results from Adeona’s clinical study evaluating
reaZin for the dietary management of Alzheimer’s disease and
mild cognitive impairment were presented last week at the 63rd
Annual Meeting of the American Academy of Neurology. In the
patients administered reaZin, the primary outcome of
increasing serum zinc and decreasing serum free copper was
effectively demonstrated. In addition, the average cognitive
function of the placebo group declined over 6 months in comparison
to patients managed with reaZin. The cognitive function
trends favoring the patients administered reaZin were
observed in all three standardized cognitive tests and suggest that
reaZin may provide an important dietary benefit to
Alzheimer’s disease patients.
“Executing this agreement for the manufacturing of our product
candidate, reaZin, is an important step for
commercialization,” stated James S. Kuo, M.D., M.B.A., Adeona’s
Chief Executive Officer. “With the recent news that revised
guidelines for diagnosing Alzheimer’s disease could double the
population size, we are excited that reaZin may be of
benefit to this growing population, particularly in the earlier
stages.”
About Medical Foods
A medical food (1) is intended for the specific dietary
management of a disease or condition for which distinctive
nutritional requir
‘/>”/>
